BioInItaly Newsletter

La vetrina del biotech italiano all’estero

N.5_2018/ NEWSLETTER MENSILE

20 giu, 2018

The Italian Biotech industry – Facts & Figures
The new report on the Italian biotech industry, drafted thanks to the consolidated collaboration between Assobiotec (Italian Association for the Development of Biotechnology, part of Federchimica) and ENEA (National Agency for New Technologies, Energy and Sustainable Economic Development) is on-line at this link: http://bit.ly/ReportBiotech2018ENG. The analysis offers an update on the current Italian biotech industry in 2017. These are the main themes: the figures of Italian biotech, a chapter on research and development activities, a snapshot of the healthcare, agriculture and veterinary medicine, industry and environment sectors, a focus on bioeconomy and measures to support innovation. The data collected within the framework of the National Statistical Programme will be merged into the statistics on the biotechnology industry edited by the
OECD – Organisation for Economic Cooperation and Development, whose methodology is adopted in this study.

Nerviano Medical Sciences announces Collaboration and License Agreement with Merck to discover small molecule inhibitors of certain anticancer targets
Nerviano Medical Sciences, the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies in Europe, announced an agreement with Merck, a leading science and technology company, under which the two companies will collaborate on the discovery of small molecule inhibitors for development as anticancer agents.
Under the terms of the agreement, Nerviano Medical Sciences grants Merck an exclusive right to conduct joint research and to develop, manufacture and commercialize inhibitors of certain molecular targets in the area of DNA damage repair. More info: https://www.nervianoms.com/en/news-media-en/press-release/media-releases-news-2018/nerviano-medical-sciences-announces-collaboration-and-license-agreement-with-merck-to-discover-small-molecule-inhibitors-of-certain-anticancer-targets/

Diasorin introduces primer pair reagents for use in molecular testing: Anaplasma Phagocytophilum, Ehrlichia and Babesia
DiaSorin announced the launch of three new primer pairs for use in laboratory-developed molecular tests. 
The new offerings join DiaSorin Molecular’s menu of more than 60 molecular reagents for bacterial, viral and fungal targets in addition to human genetic mutations. The primer pairs are classified as Analyte Specific Reagents (ASRs), which can be used by high complexity laboratories to develop their own laboratory developed tests (LDTs). Tick-borne infections are more than doubling between 2004 and 2016 mainly due to the increase in human travel, which can result in the spread of tick-borne bacteria to new locations, climate and habitat changes affecting animals that harbor ticks. More info: http://www.diasorin.com/sites/default/files/allegati_pressrel/pr_diasorin_asr_eng.pdf

Chiesi signs a deal with StartUp Health: first investment in the digital area
Chiesi has signed a strategic deal with StartUp Health, a global health innovation company focused on achieving Health Moonshots. StartUp Health has the largest digital health-focused portfolio in the world, consisting of over 235 companies applying technology to solve key challenges such as creating global access to care, reducing cost and curing disease. With this achievement, Chiesi completes its first strategic deal in the technology space. This partnership with StartUp Health is a significant step forward in Chiesi’s technology & digital health strategy. Chiesi plans to combine its deep expertise in respiratory care, neonatology, special care and rare diseases with StartUp Health’s extensive global network of innovative companies and partners, stimulating research and the availability of therapeutic solutions for our patients. More info: http://www.chiesi.com/en/chiesi-signs-a-deal-with-startup-health-first-investment-in-the-digital-area/

MolMed: new and relevant data on the therapeutic potential of NGR-hTNF in brain lymphomas presented at ASCO
MolMed Spa, medical biotechnology company focusing on research, development, manufacturing, and clinical validation of Cell&Gene therapies to treat cancer and rare diseases, announces that new and relevant data on the proprietary therapeutic agent NGR-hTNF in brain lymphomas resulted from the independent study “INGRID”, presented by Dr Andrés J. M. Ferreri, Head of the Lymphoma Unit of IRCCS San Raffaele Hospital in Milan, and principal investigator of the trial, during the session “Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia” at ASCO, the annual meeting of the American Society of Clinical Oncology held in Chicago. The study, a phase II prospective trial, was designed by Dr Andrés J. M. Ferreri, in order to assess the activity of NGR-hTNF, in combination with standard chemotherapy (R-CHOP), in patients with primary central nervous system lymphoma, refractory or resistant to standard treatments. 
More info: http://www.molmed.com/sites/default/files/uploads/press-releases/3353/3353_1528118439.pdf

AstraZeneca, the EU approves Tagrisso for 1st-line treatment of EGFR-mutated non-small cell lung cancer 
The European Commission has granted marketing authorisation for Tagrisso (osimertinib) as monotherapy for the 1st-line treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. The approval is based on results from the Phase III FLAURA trial published in the New England Journal of Medicine.
The approval follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. More info: https://www.astrazeneca.com/media-centre/press-releases/2018/the-eu-approves-tagrisso-for-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer-08062018.html

InnovHeart Srl, a developer of novel transcatheter mitral valve replacement (TMVR) systems, announces the appointment of veteran medical device executive Keith D. Dawkins, M.D. to its Board of Directors.
InnovHeart Srl, a developer of novel transcatheter mitral valve replacement (TMVR) systems for the treatment of mitral valve disease, announces the appointment of veteran medical device executive Keith D. Dawkins, M.D., to a newly created position on its Board of Directors.
Dr. Dawkins has more than 35 years’ experience as both a practicing physician and an executive within the medical device industry. He currently also serves at 4Tech Inc. as Chief Medical Officer, and is a member of the Boards of Avicena LLC and JenaValve Technology Inc. Dr. Dawkins previously served as Executive Vice President and Global Chief Medical Officer at Boston Scientific for all divisions, 2012 – 2017. His responsibilities included enhancing the company’s global clinical programs and strategies. Before that, he served as Senior Vice President and CMO for the Boston Scientific Cardiology Rhythm and Vascular Group. Prior to joining Boston Scientific, Dr. Dawkins was a practicing interventional cardiologist for over 20 years in the U.K. He has earned a series of clinical, research and academic distinctions, including a post-doctoral research fellowship at Stanford University as a Fulbright Scholar. Dr. Dawkins also served as President of the British Cardiovascular Intervention Society and held numerous appointments on hospital, regional and national committees, including the National Institute for Health and Clinical Excellence (NICE). He has been an author on more than 750 academic publications and presentations on a variety of cardiac topics.
More info: http://www.prweb.com/releases/2018/05/prweb15466345.htm